Global Health
Authors
David Relman
News Type
News
Date
Paragraphs

“Microbes have the ability to evolve and try lots of genetic variations on a theme very quickly,” David Relman, MD, professor of microbiology at Stanford University and member of the standing committee on Emerging Infectious Diseases and 21st Century Threats at the National Academies of Science, Engineering and Medicine, said during a recent episode of Healthcare Strategies.

Healthcare Strategies · Assessing the Value of Using Genomic Data To Guide Population Health

 

Read the rest at Health IT Analytics

Hero Image
Turquoise background Getty Images
All News button
1
Subtitle

Genomic data could benefit population health efforts during the COVID-19 pandemic, but the US has to overcome several barriers before it can fully leverage this information.

-

Pascal Geldsetzer, PhD 
Assistant Professor of Medicine in the Division of Primary Care and Population Health

Title:  Regression Discontinuity in Electronic Health Record Data

Abstract: Regression discontinuity in electronic health record (EHR) data combines the main advantage of randomized controlled trials (causal inference without needing to adjust for confounders) with the large size, low cost, and representativeness of observational studies in routinely collected medical data. Regression discontinuity could be an important tool to help clinical medicine move away from a “one size fits all” approach because, along with the increasing size and availability of EHR data, it would allow for a rigorous examination of how treatment effects vary across highly granular patient subgroups. In addition, given the broad range of health outcomes recorded in EHR data, this design could be used to systematically test for a wide range of unexpected beneficial and adverse health effects of different treatments. I will talk about the broad motivation for this research and discuss examples from some of our ongoing work in this area. If there is time, I will also discuss some of my ongoing research on improving healthcare services for chronic conditions in low- and middle-income country settings. 

Zoom Meeting

Register in advance for this meeting:
https://stanford.zoom.us/meeting/register/tJYpcO2ppzooGNdbf8o1OxXNUWd3rukNEb7i 

After registering, you will receive a confirmation email containing information about joining the meeting.

0
Stanford Medicine Innovation Professor
alyce_profile_2022.jpg PhD, MPP

Alyce Adams is a Professor of Health Policy and of Epidemiology and Population Health in the Stanford School of Medicine; Associate Chair, Partnership and Community Engagement for the Department of Health Policy; and Associate Director for Health Equity and Community Engagement in the Stanford Cancer Institute. Focusing on racial and socioeconomic disparities in chronic disease treatment outcomes, Dr. Adams' interdisciplinary research seeks to evaluate the impact of changes in drug coverage policy on access to essential medications, understand the drivers of disparities in treatment adherence among insured populations, and test strategies for maximizing the benefits of treatment outcomes while minimizing harms through informed decision-making. Prior to joining Stanford School of Medicine, Dr. Adams was Associate Director for Health Care Delivery and Policy and a Research Scientist at the Kaiser Permanente Division of Research, as well as a Professor at the Bernard J. Tyson Kaiser Permanente School of Medicine. From 2000 to 2008, she was an Assistant Professor in the Department of Population Medicine (formerly Ambulatory Care and Prevention) at Harvard Medical School and Harvard Pilgrim Health care. She received her PhD in Health Policy and an MPP in Social Policy from Harvard University. She is Vice Chair of the Board of Directors for AcademyHealth and a former recipient of the John M. Eisenberg Excellence in Mentoring Award from Agency for Healthcare Research and Quality and an invited lecturer on racial disparities in health care in the 2014/2015 National Institute of Mental Health Director’s Innovation Speaker Series.

Professor, Epidemiology and Population Health
Professor, Health Policy
Professor, Pediatrics (by courtesy)
CV
Date Label
Authors
News Type
News
Date
Paragraphs

 

 

Originally for NPR

Hero Image
COVID-19 virus Alissa Eckert, MSMI, Dan Higgins, MAMS
All News button
1
Subtitle

Coronavirus variants are spreading in the United States, threatening to spark yet a new surge. Is there a good defense? NPR health correspondent Rob Stein talks to CISAC Senior Fellow David Relman.

Authors
David Relman
News Type
News
Date
Paragraphs

Dr. David Relman, an esteemed microbiologist, kept returning to the same conclusion as he fielded questions as a guest at Rep. Jerry McNerney’s virtual town hall.

No matter what your fears or concerns, getting a COVID-19 vaccine, Relman said, is far better and safer than getting the virus.

“Were you to come visit any of us in a hospital setting and see what it looks like to be critically ill with COVID, you would be doing everything humanly possible to avoid it,” Relman said at Thursday’s town hall. “It is a miserable, miserable disease. You do not want it.”

Read the rest at The Record

Hero Image
Illustration of coronavirus CDC/Alissa Eckert, MSMI; Dan Higgins, MAMS
All News button
1
Subtitle

Dr. David Relman, an esteemed microbiologist, kept returning to the same conclusion as he fielded questions as a guest at Rep. Jerry McNerney’s virtual town hall. No matter what your fears or concerns, getting a vaccine, Relman said, is far better and safer than getting the virus.

-

Title: Research in Progress: Doug Owens - Development of the New USPSTF Guidelines on Screening for Lung Cancer and Colorectal Cancer

Brief Abstract: 

Discuss the development of the two new draft guidelines from the U.S. Preventive Services Task Force.  Screening for lung cancer and colorectal cancer are two of the most complex and important cancer screening guidelines in the USPSTF portfolio.  Describing the methods the USPSTF uses, including the evidence reviews and modeling that helped us create these new recommendations.

 

Zoom Meeting 

Register in advance for this meeting: 
https://stanford.zoom.us/meeting/register/tJcuf-2sqzkoE93jEPn9deZKTTBJoze-2d6u 

After registering, you will receive a confirmation email containing information about joining the meeting.

Encina Commons, Room 201 
615 Crothers Way Stanford, CA 94305-6006 

Executive Assistant: Soomin Li, soominli@stanford.edu
Phone: (650) 725-9911

(650) 723-0933 (650) 723-1919
0
Henry J. Kaiser, Jr. Professor
Professor, Health Policy
Senior Fellow, Freeman Spogli Institute for International Studies
Professor, Management Science & Engineering (by courtesy)
doug-headshot_tight.jpeg MD, MS

Douglas K. Owens is the Henry J. Kaiser, Jr. Professor, Chair of the Department of Health Policy in the Stanford University School of Medicine and Director of the Center for Health Policy (CHP) in the Freeman Spogli Institute for International Studies (FSI). He is a general internist, a Professor of Management Science and Engineering (by courtesy), at Stanford University; and a Senior Fellow at the Freeman Spogli Institute for International Studies.

Owens' research includes the application of decision theory to clinical and health policy problems; clinical decision making; methods for developing clinical guidelines; decision support; comparative effectiveness; modeling substance use and infectious diseases; cardiovascular disease; patient-centered decision making; assessing the value of health care services, including cost-effectiveness analysis; quality of care; and evidence synthesis.

Owens chaired the Clinical Guidelines Committee of the American College of Physicians for four years. The guideline committee develops clinical guidelines that are used widely and are published regularly in the Annals of Internal Medicine. He was a member and then Vice-Chair and Chair of the U.S. Preventive Services Task Force, which develops national guidelines on preventive care, including guidelines for screening for breast, colorectal, prostate, and lung cancer. He has helped lead the development of more than 50 national guidelines on treatment and prevention. He also was a member of the Second Panel on Cost Effectiveness in Health and Medicine, which developed guidelines for the conduct of cost-effectiveness analyses.

Owens also directed the Stanford-UCSF Evidence-based Practice Center. He co-directs the Stanford Health Services Research Program, and previously directed the VA Physician Fellowship in Health Services Research, and the VA Postdoctoral Informatics Fellowship Program.

Owens received a BS and an MS from Stanford University, and an MD from the University of California-San Francisco. He completed a residency in internal medicine at the University of Pennsylvania and a fellowship in health research and policy at Stanford. Owens is a past-President of the Society for Medical Decision Making. He received the VA Undersecretary’s Award for Outstanding Achievement in Health Services Research, and the Eisenberg Award for Leadership in Medical Decision Making from the Society for Medical Decision Making. Owens also received a MERIT award from the National Institutes on Drug Abuse to study HIV, HCV, and the opioid epidemic. He was elected to the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP.)

Chair, Department of Health Policy, School of Medicine
Director, Center for Health Policy, Freeman Spogli Institute for International Studies
CV
Date Label
Authors
News Type
News
Date
Paragraphs

Researchers have long known that the number of human infections from the bat-borne Nipah virus fluctuates from year to year. Now, a new study provides insights into the reasons why.

In a Stanford News Q&A, Stanford epidemiologist Stephen Luby, MD, discussed the findings and how they relate to SARS-CoV-2, the virus that causes COVID-19.

Read the rest at Scope

Hero Image
Two bats hanging upside down Charles J. Sharp of Sharp Photography / Wikimedia
All News button
1
Subtitle

Researchers have long known that the number of human infections from the bat-borne Nipah virus fluctuates from year to year. A new study provides insights into the reasons why. Stanford epidemiologist Stephen Luby, MD, discussed the findings and how they relate to COVID-19.

Paragraphs

With vaccines against SARS-CoV-2, the virus that causes Covid-19, on the near-term horizon, U.S. policymakers are focusing on how to ensure that Americans get vaccinated. This challenge has been compounded by reports that White House officials are exerting undue influence over the agencies that would ordinarily lead such efforts, the Food and Drug Administration and the Centers for Disease Control and Prevention.

All Publications button
1
Publication Type
Commentary
Publication Date
Journal Publisher
STAT News
Authors
Michelle Mello
Number
2020
Authors
News Type
News
Date
Paragraphs

Water sensitive cities show how holistic approaches can counter the health and wellbeing problems associated with urban dryness. About 1.6 billion people live in countries with water scarcity, and this number is projected to double in two decades.

Read the rest at  BMJ

Hero Image
Dry town Burak Kara / Stringer/ GettyImages
All News button
1
Subtitle

Water sensitive cities show how holistic approaches can counter the health and wellbeing problems associated with urban dryness. About 1.6 billion people live in countries with water scarcity, and this number is projected to double in two decades.

Authors
Stephen P. Luby
News Type
Q&As
Date
Paragraphs

A little known virus may have a lot to teach us about dealing with COVID-19. Discovered 20 years ago, Nipah virus can spread from bats or pigs to humans. Found only in South and South East Asia so far, it kills nearly three-quarters of the people it infects. There is no vaccine for it and no cure, and it has many strains capable of spreading from person to person, increasing the chances of a strain emerging with the ability to rapidly spread beyond the region.

Read the rest at  Stanford News

Hero Image
Bat hanging from a branch Jakub Hałun / Wikimedia Commons
All News button
1
Subtitle

Stanford epidemiologist Stephen Luby discusses surprising results of a recent study on Nipah virus, a disease with no vaccine and a mortality rate of up to 70 percent.

Subscribe to Global Health